Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...

In addition, Formycon will present study data focusing on the pharmacokinetics of the ustekinumab biosimilar candidate FYB202 at the United European Gastroenterology (UEG) Week from October 12 to 15, ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of ...

The Control Group received standard treatment for plaque psoriasis, which included topical ... which are crucial metrics for improving patient outcomes in chronic conditions like psoriasis. Moreover, ...